Login to Your Account

Other News To Note

Wednesday, August 29, 2012

• Debiopharm Group, of Lausanne, Switzerland, treated its first patient in an open-label, Phase III trial of triptorelin pamoate 22.5 mg 6-month formulation in children with central precocious puberty.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription